Niraparib Shrinks BRCA-Mutated Prostate Tumors.
Niraparib showed promising signs of efficacy in the phase II GALAHAD trial of men with advanced prostate cancer whose tumors harbor mutations in the DNA damage-response pathway, especially among patients with gene defects in BRCA1 or BRCA2.